Home/Pipeline/Tolebrutinib

Tolebrutinib

Multiple Sclerosis

Phase 3ActiveN/A

Key Facts

Indication

Multiple Sclerosis

Phase

Phase 3

Status

Active

Company

Sanofi

About Sanofi

Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.

View full company profile

Therapeutic Areas

Immunology Oncology Rare Diseases Neurology Vaccines

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Evobrutinib	Merck KGaA	Phase 3	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active
REBIF (interferon beta-1a)	EMD Serono	Approved	Active (Lifecycle Management)